Market Place
Sourcing Support
Genmab Announces Initiation of Share Buy-Back Program
25 Mar 2025 //
GLOBENEWSWIRE
Genmab To Defend Against Trade Secret Claims By AbbVie
21 Mar 2025 //
GLOBENEWSWIRE
Passing of Genmab A/S Annual General Meeting
12 Mar 2025 //
GLOBENEWSWIRE
Genmab A/S Board Grants Restricted Stock Units and Warrants
12 Mar 2025 //
GLOBENEWSWIRE
Genmab A/S managerial employees and associates` share transaction
12 Mar 2025 //
GLOBENEWSWIRE
Genmab announces Johnson & Johnson decision on HexaBody-CD38
10 Mar 2025 //
GLOBENEWSWIRE
Genmab A/S managerial employees and associates` share transaction
04 Mar 2025 //
GLOBENEWSWIRE
Genmab Grants Restricted Stock & Warrants To Employees
28 Feb 2025 //
GLOBENEWSWIRE
Genmab Execs & Associates Conduct Transactions In Company Shares
28 Feb 2025 //
GLOBENEWSWIRE
Genmab`s Capital Increases Due to Employee Warrant Exercise
25 Feb 2025 //
GLOBENEWSWIRE
Epkinely Gets Japan MHLW Approval For R/R Follicular Lymphoma
20 Feb 2025 //
GLOBENEWSWIRE
Epkinely Approved In Japan For Relapsed Follicular Lymphoma
20 Feb 2025 //
BUSINESSWIRE
Genmab to Join Fireside Chat at 45th Annual TD Cowen Conference
19 Feb 2025 //
GLOBENEWSWIRE
Notice to Convene the Annual General Meeting of Genmab A/S
13 Feb 2025 //
GLOBENEWSWIRE
Genmab Publishes 2024 Annual Report
12 Feb 2025 //
GLOBENEWSWIRE
Genmab Files Annual Report with Securities and Exchange Commission
12 Feb 2025 //
GLOBENEWSWIRE
Grant of Restricted Stock Units and Warrants to Employees in Genmab
23 Jan 2025 //
GLOBENEWSWIRE
Genmab to Present at 43rd Annual J.P. Morgan Healthcare Conference
03 Jan 2025 //
GLOBENEWSWIRE
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11 Dec 2024 //
GLOBENEWSWIRE
Roche`s subQ Lunsumio matches IV version in lymphoma
10 Dec 2024 //
FIERCE PHARMA
Epcoritamab Induces Durable Responses in DLBCL as Treatment
09 Dec 2024 //
GLOBENEWSWIRE
Epcoritamab Induces Responses in DLBCL as Mono & Combo Treatment
09 Dec 2024 //
BUSINESSWIRE
Epcoritamab Monotherapy Shows High Response in Relapsed CLL Patients
08 Dec 2024 //
GLOBENEWSWIRE
Epcoritamab Combo Therapy Effective in Relapsed Follicular Lymphoma
07 Dec 2024 //
GLOBENEWSWIRE
Genmab buys 2nd antibody from Scancell in deal worth up to $630M
04 Dec 2024 //
FIERCE BIOTECH
Genmab Employees Report Transactions with Shares & Securities
03 Dec 2024 //
GLOBENEWSWIRE
Capital Increase in Genmab from Employee Warrant Exercise
03 Dec 2024 //
GLOBENEWSWIRE
Genmab to Present at Citi’s Global Healthcare Conference
25 Nov 2024 //
GLOBENEWSWIRE
Genmab open to more M&A if it makes `strategic sense
22 Nov 2024 //
FIERCE BIOTECH
Grant of Restricted Stock Units & Warrants to Employees in Genmab
21 Nov 2024 //
GLOBENEWSWIRE
Genmab axes 3 programs to focus on plumped-up pivotal pipeline
08 Nov 2024 //
FIERCE BIOTECH
Genmab Reports Financials for First Nine Months of 2024
06 Nov 2024 //
GLOBENEWSWIRE
Genmab Showcases Epcoritamab Development at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Genmab to Present at Jefferies London Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
Genmab to Present Epcoritamab-bysp Program at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
Genmab Announces Net Sales of Darzalex for Third Quarter of 2024
15 Oct 2024 //
GLOBENEWSWIRE
Major Shareholder Announcement
04 Oct 2024 //
GLOBENEWSWIRE
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26 Sep 2024 //
GLOBENEWSWIRE
Rinatabart Sesutecan Shows Promise In Ovarian And Endometrial Cancers
15 Sep 2024 //
GLOBENEWSWIRE
Genmab Announces Capital Increase From Warrant Exercise
10 Sep 2024 //
GLOBENEWSWIRE
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
TEPKINLY Gets Second EC Approval For Relapsed Follicular Lymphoma
19 Aug 2024 //
GLOBENEWSWIRE
Genmab shuffles C-Suite on commercialization, manufacturing as portfolio grows
19 Aug 2024 //
FIERCE PHARMA
Genmab Announces Changes to its Executive Committee
16 Aug 2024 //
GLOBENEWSWIRE
Capital Increase in Genmab as a Result of Employee Warrant Exercise
13 Aug 2024 //
GLOBENEWSWIRE
Genmab A/S Reports Insider Transactions
13 Aug 2024 //
GLOBENEWSWIRE
Genmab Updates 2024 Financial Guidance
08 Aug 2024 //
GLOBENEWSWIRE
Genmab Announces Financial Results for the First Half of 2024
08 Aug 2024 //
GLOBENEWSWIRE
BioNTech ends work on Genmab-partnered bispecific antibody acasunlimab
05 Aug 2024 //
FIERCE BIOTECH
Genmab Takes Full Control of Acasunlimab Development Program
03 Aug 2024 //
GLOBENEWSWIRE
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
17 Jul 2024 //
GLOBENEWSWIRE
Epcoritamab gets Positive CHMP Opinion for Relapsed Follicular Lymphoma
28 Jun 2024 //
GLOBENEWSWIRE
Completion of Share Buy-back Program
27 Jun 2024 //
GLOBENEWSWIRE
FDA grants accelerated approval to epcoritamab-bysp
27 Jun 2024 //
FDA
Genmab Us, Inc. Biologic Epcoritamab-Bysp Receives Approval in US
26 Jun 2024 //
FDA
EPKINLY Approved By FDA For Relapsed Follicular Lymphoma
26 Jun 2024 //
BUSINESSWIRE
Transactions in Connection with Share Buy-back Program
24 Jun 2024 //
GLOBENEWSWIRE
Capital Increase in Genmab as a Result of Employee Warrant Exercise
18 Jun 2024 //
GLOBENEWSWIRE
Transactions In Connection With Share Buy-back Program
17 Jun 2024 //
GLOBENEWSWIRE
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12 Jun 2024 //
GLOBENEWSWIRE
